关注
Hirva Mamdani
Hirva Mamdani
Karmanos Cancer Institute/Wayne State University
在 karmanos.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Immunotherapy in lung cancer: current landscape and future directions
H Mamdani, S Matosevic, AB Khalid, G Durm, SI Jalal
Frontiers in immunology 13, 823618, 2022
1492022
Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO living guideline
N Singh, S Temin, S Baker Jr, E Blanchard, JR Brahmer, P Celano, ...
Journal of Clinical Oncology 40 (28), 3323-3343, 2022
1212022
Characterization of KRAS mutation subtypes in non–small cell lung cancer
J Judd, N Abdel Karim, H Khan, AR Naqash, Y Baca, J Xiu, ...
Molecular cancer therapeutics 20 (12), 2577-2584, 2021
932021
Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States
R Jinjuvadia, S Liangpunsakul
Journal of Clinical Gastroenterology 49 (6), 506-511, 2015
932015
Novel therapies in small cell lung cancer
H Mamdani, R Induru, SI Jalal
Translational lung cancer research 4 (5), 533, 2015
752015
Blood-based tumor biomarkers in lung cancer for detection and treatment
H Mamdani, S Ahmed, S Armstrong, T Mok, SI Jalal
Translational Lung Cancer Research 6 (6), 648, 2017
732017
Histone deacetylase inhibition in non-small cell lung cancer: hype or hope?
H Mamdani, SI Jalal
Frontiers in cell and developmental biology 8, 582370, 2020
642020
Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies
M Johnson, A El-Khoueiry, N Hafez, N Lakhani, H Mamdani, J Rodon, ...
Clinical Cancer Research 27 (16), 4521-4530, 2021
412021
Excellent Response to Anti-PD1 therapy in a Patient with Hepatocellular Carcinoma: Case Report and Review of Literature
H Mamdani, H Wu, BH O'Neil, A Sehdev
Discovery Medicine, 2017
342017
Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other …
ML Johnson, GK Dy, H Mamdani, A Dowlati, AJ Schoenfeld, JM Pacheco, ...
Journal of Clinical Oncology 40 (16_suppl), 8566-8566, 2022
292022
Radium-223 in heavily pretreated metastatic castrate-resistant prostate cancer
D Modi, C Hwang, H Mamdani, S Kim, H Gayar, U Vaishampayan, ...
Clinical genitourinary cancer 14 (5), 373-380. e2, 2016
292016
Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO living guideline, version 2022.2
DH Owen, N Singh, N Ismaila, E Blanchard, P Celano, N Florez, D Jain, ...
Journal of Clinical Oncology 41 (5), e10-e20, 2023
232023
A phase II trial of adjuvant durvalumab following trimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma: a big ten cancer research …
H Mamdani, B Schneider, SM Perkins, HN Burney, PM Kasi, LI Abushahin, ...
Frontiers in Oncology 11, 736620, 2021
202021
Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors
A Tolcher, H Mamdani, P Chalasani, F Meric-Bernstam, M Gazdoiu, ...
Cancer Research 81 (13_Supplement), CT016-CT016, 2021
202021
Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO living guideline, version 2023.1
N Singh, IA Jaiyesimi, N Ismaila, NB Leighl, H Mamdani, T Phillips, ...
Journal of Clinical Oncology 41 (15), e51-e62, 2023
182023
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16 …
GA Durm, H Mamdani, SK Althouse, SK Jabbour, AK Ganti, SI Jalal, ...
Journal of Clinical Oncology 40 (16_suppl), 8509-8509, 2022
182022
Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO living guideline, version 2023.1
N Singh, IA Jaiyesimi, N Ismaila, NB Leighl, H Mamdani, T Phillips, ...
Journal of Clinical Oncology 41 (15), e42-e50, 2023
172023
Coronavirus disease 2019 outcomes, patient vaccination status, and cancer-related delays during the omicron wave: a brief report from the TERAVOLT analysis
CM Bestvina, JG Whisenant, V Torri, A Cortellini, H Wakelee, S Peters, ...
JTO Clinical and Research Reports 3 (8), 100335, 2022
162022
The effects of HER2 alterations in EGFR mutant non-small cell lung cancer
M Nagasaka, V Singh, Y Baca, A Sukari, C Kim, H Mamdani, AI Spira, ...
Clinical lung cancer 23 (1), 52-59, 2022
162022
Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, a multicenter, multicohort, open-label, phase 2 trial (cohort 4)
R Cornelissen, A Prelaj, S Sun, C Baik, M Wollner, EB Haura, H Mamdani, ...
Journal of Thoracic Oncology 18 (8), 1031-1041, 2023
152023
系统目前无法执行此操作,请稍后再试。
文章 1–20